Data investigation
A Composite Is Only Its Components
A reanalysis found tirzepatide getting far more patients to three or more treatment targets. The comparator was semaglutide at 1 mg, and the gap was carried by two of the four targets.
A reanalysis of SURPASS-2 asked how many standard treatment targets (blood sugar, blood pressure, cholesterol and weight) each drug got patients to, and tirzepatide won at every dose.[1] Before that means anything, note what was compared: tirzepatide at up to 15 mg against semaglutide at 1 mg, the diabetes dose. Then look at which targets moved.
The dose question first
That is not a scandal. SURPASS-2 was a diabetes trial, 1 mg was the licensed diabetes dose when it ran, and comparing against an approved comparator at an approved dose is legitimate design. What it means is narrower than the sentence people extract from it. “Tirzepatide gets more patients to target than semaglutide 1 mg in type 2 diabetes” is supported. “Tirzepatide beats semaglutide” is not the same claim.
The trial that does compare them at their weight-management doses is a different study, and its quality-of-life analysis is covered in the mental health score that did not move.
What the analysis did
The authors took 1,879 participants from SURPASS-2 and scored each against four standard targets and four stricter ones, at 40 weeks.
| Measure | Standard | Intensive |
|---|---|---|
| HbA1c | < 7% | < 6.5% |
| Blood pressure | < 140/90 | < 130/80 |
| LDL cholesterol | < 1.8 mmol/l | < 1.4 mmol/l |
| Weight loss | > 10% | > 15% |
At baseline almost nobody was near all four. On the standard set, 19% met none and only 21% met two or more. On the intensive set, 58% met none and just 4% met two.
| Semaglutide 1 mg | Tirze 5 mg | Tirze 10 mg | Tirze 15 mg | |
|---|---|---|---|---|
| Standard targets | 34% | 42% | 53% | 57% |
| Intensive targets | 8% | 15% | 20% | 29% |
Which components carried it
“Three of four targets” sounds like all-round metabolic control. The odds ratios show where the difference actually came from.
| Target | Odds ratio (95% CI) |
|---|---|
| HbA1c < 7% | 1.50 (1.12–2.00) |
| HbA1c < 6.5% | 1.88 (1.49–2.36) |
| Weight loss > 10% | 2.72 (2.14–3.47) |
| Weight loss > 15% | 3.86 (2.69–5.55) |
| Blood pressure, intensive | 1.45 (1.17–1.81) |
| LDL cholesterol | not among the significant results |
Blood sugar and weight do the work, and weight does most of it, with nearly four times the odds of losing more than 15%. Blood pressure contributes only at the stricter threshold. LDL cholesterol does not appear at all.
A composite counts its components equally. A drug does not affect them equally.
What is useful here
Setting the framing aside, the underlying observation matters clinically. Most people with type 2 diabetes are not near their targets (in this trial, only 21% met two or more of the four at baseline), and getting to several at once has historically meant stacking several drugs, each with its own side effects and its own adherence cost.
A single agent moving two of the four substantially is a real simplification, and 57% reaching three or more standard targets is a large number in this population by any historical comparison. Put plainly, this drug is very good at two of these four things, and that turns out to be enough to move a composite a long way.
One structural note: the targets were applied to the trial data afterward rather than being its endpoints. That is standard and reasonable for this kind of question, and it is still a post hoc analysis.
Frequently Asked Questions
References
- 1.Neves JS, Leite AR, Vale C, et al. Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial Diabetologia. 2026. PMID: 41419618.
Compare the sellers
Related research
Normal Blood Sugar Is Not Remission
In a two-year trial against real-world care, 60.2% of people on tirzepatide reached an HbA1c below 5.7%. Every one of them was still taking the drug, and that distinction has a practical edge.
7 min read
An Oral Pill in a Diabetes Population
Over 72 weeks a daily tablet took 9.6% off the scale for people carrying obesity alongside type 2 diabetes. Why we will not set that figure beside the injectable trials.
7 min read
Tirzepatide in Ten- to Seventeen-Year-Olds
Youth-onset type 2 diabetes moves faster and responds worse than the adult disease. In 99 children aged 10 to 17, tirzepatide cut HbA1c by 2.23% while the placebo group's blood sugar rose.
6 min read
One Injection Instead of Twenty-Eight
Someone on basal-bolus insulin injects roughly 28 times a week. A trial tested replacing that with one weekly combination injection, matching blood sugar control while cutting serious hypoglycemia by 88%.
6 min read
Comparing Trials That Never Met
We refused a cross-trial comparison in an earlier article. This article runs the methodologically proper version of it, and explains why it appears to contradict a head-to-head trial without actually doing so.
7 min read
Real, and Below the Threshold
Semaglutide improves patient-reported physical functioning by 1.71 points, with an interval excluding zero. The threshold at which a patient notices a change is 3.7 points. Both are true at once.
6 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
altRX
Compounded semaglutide from $89/month at the same price at every dose
From $89/mo
Get started →CoreAge Rx
Flat-priced compounded semaglutide at $79 a month, any dose
From $79/mo
Get started →Embody
A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
From $79/mo
Get started →